Withdrawals due to adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in withdrawals due to adverse events Due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.75 [0.46, 1.21]
1165 participants
High
BASDAI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
190 participants
Moderate
BASFI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
356 participants
High
BASMI Scale from 0 to 10 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Radiographic progression · patients with axSpA (AS and nr‐axSpA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.69 [0.36, 7.97]
671 participants
Moderate
Function: mean change in pain with movement from baseline on4‐point (0 to 3, 0 best function) Likert scale · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Global assessment of treatment success · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Health‐related quality of life (mental) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · acute gout
Non‐selective NSAIDs probably leads to higher withdrawals due to adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
RR 2.34 [1.33, 4.14]
Studies not reported
Moderate
Total adverse events · acute gout
Non‐selective NSAIDs probably leads to higher total adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
RR 1.94 [1.36, 2.78]
Studies not reported
Moderate
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Swelling (mean) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · acute gout
1 finding from 1 review
Global assessment of treatment success · acute gout
Low‐dose colchicine showed no clear difference in participant global assessment of treatment success: Completely… compared with NSAIDs (low certainty).
1 finding from 1 review
Reduction of inflammation ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants reporting an adverse event · acute gout
Low‐dose colchicine showed no clear difference in total number of participants reporting adverse events compared with NSAIDs (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
The review found no eligible studies for this question.
1 finding from 1 review